Abeona director sells 14,814 shares for tax obligations

Abeona Therapeutics director Donald A. Wuchterl reported a small stock sale mainly for tax purposes.

Accepted by SEC EDGAR 02/02/2026 - 06:59 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Abeona Therapeutics director Donald A. Wuchterl reported a small stock sale mainly for tax purposes. On 02/02/2026, he sold 14,814 shares of Abeona Therapeutics common stock at a weighted average price of $5.0906 per share to cover tax obligations from vesting restricted stock awards.

After this transaction, he directly owned 167,935 shares of Abeona common stock. The shares were sold in multiple trades within a narrow price range from $5.09 to $5.12 per share.

Insider Trade Summary

Net Seller: 14,814 shares

Net Sell 1 txn

Insider Wuchterl Donald A.

Role Director

Sold 14,814 shs ($75K)

Share of Position Sold 8.1%

Type	Security	Shares	Price	Value
Sale	Common Stock	14,814	$5.0906	$75K

Holdings After Transaction: Common Stock — 167,935 shares (Direct)

Holdings Before and After: Common Stock, 182,749 to 167,935 shares (Direct)

Other Insiders: 7 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.12 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Abeona Therapeutics (ABEO) disclose for Donald A. Wuchterl?

Abeona Therapeutics reported that director Donald A. Wuchterl sold 14,814 shares of common stock on 02/02/2026. The sale was primarily to cover tax obligations arising from the vesting of restricted stock awards, according to the Form 4 footnotes.

At what price did the Abeona Therapeutics (ABEO) director sell his shares?

The reported weighted average sale price was $5.0906 per share. The Form 4 notes that the 14,814 shares were sold in multiple transactions, with individual trade prices ranging from $5.09 to $5.12 per share on the transaction date.

How many Abeona Therapeutics (ABEO) shares does the director own after the Form 4 sale?

Following the reported sale, director Donald A. Wuchterl directly owned 167,935 shares of Abeona Therapeutics common stock. This post-transaction balance is shown in the Form 4 as the amount of securities beneficially owned after the transaction.

Why did the Abeona Therapeutics (ABEO) director sell shares according to the Form 4?

The Form 4 states the sale was made to cover tax obligations related to the vesting of restricted stock awards. This indicates the transaction was linked to equity compensation rather than a discretionary open-market sale for portfolio rebalancing.

What does the weighted average price mean in the Abeona Therapeutics (ABEO) Form 4 filing?

The weighted average price of $5.0906 reflects multiple trades executed between $5.09 and $5.12 per share. The director offers to provide detailed trade information, including the number of shares sold at each price, to the company, shareholders, or SEC staff upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wuchterl Donald A.

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S(1)		14,814	D	$5.0906(2)	167,935	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.12 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Donald A. Wuchterl	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.